Division of Takeda Pharmaceutical Co. Ltd.
Latest From Nycomed SPA
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
Major private equity group Blackstone buys into pharma for its first acquisition in Japan, but amid challenges in the sector, the attractions take some unraveling.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
- Contact Info
Phone: (39) 02 641 1601
Via Libero Temolo 4
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.